280 related articles for article (PubMed ID: 2897436)
1. Sipple's syndrome with liver tumors examined by iodine-131 MIBG and technetium-99m(V)-DMSA.
Ohta H; Endo K; Fujita T; Koizumi M; Konishi J; Maki A; Mori K; Ozawa K; Inoue G; Nakano Y
J Nucl Med; 1988 Jun; 29(6):1130-5. PubMed ID: 2897436
[TBL] [Abstract][Full Text] [Related]
2. Pentavalent technetium-99m (V)-DMSA uptake in a pheochromocytoma in a patient with Sipple's syndrome.
Adams BK; Fataar A; Byrne MJ; Levitt NS; Matley PJ
J Nucl Med; 1990 Jan; 31(1):106-8. PubMed ID: 1967305
[TBL] [Abstract][Full Text] [Related]
3. Detection of metastatic medullary thyroid cancer with 131I-MIBG scans in Sipple's syndrome.
Itoh H; Sugie K; Toyooka S; Kawase M; Mukaino S; Hazama F; Endo K; Torizuka K; Nakao K; Imura H
Eur J Nucl Med; 1986; 11(12):502-4. PubMed ID: 2874028
[TBL] [Abstract][Full Text] [Related]
4. Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP--an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid.
Clarke SE; Lazarus CR; Wraight P; Sampson C; Maisey MN
J Nucl Med; 1988 Jan; 29(1):33-8. PubMed ID: 2826723
[TBL] [Abstract][Full Text] [Related]
5. Poor results with technetium-99m (V) DMS and iodine-131 MIBG in the imaging of medullary thyroid carcinoma.
Hilditch TE; Connell JM; Elliot AT; Murray T; Reed NS
J Nucl Med; 1986 Jul; 27(7):1150-3. PubMed ID: 3014086
[TBL] [Abstract][Full Text] [Related]
6. Pitfall of Sipple's syndrome diagnosis by 131I-metaiodobenzylguanidine (MIBG).
Talbot JN; Coutris G; Moulonguet M; Hoang C; Perniceni T; Milhaud G
J Nucl Med Allied Sci; 1987; 31(4):337-40. PubMed ID: 2895168
[No Abstract] [Full Text] [Related]
7. Diagnostic and therapeutic potential of new radiopharmaceutical agents in medullary thyroid carcinoma.
Troncone L; Rufini V; De Rosa G; Testa A
Henry Ford Hosp Med J; 1989; 37(3-4):178-84. PubMed ID: 2576959
[TBL] [Abstract][Full Text] [Related]
8. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma.
Verga U; Muratori F; Di Sacco G; Banfi F; Libroia A
Henry Ford Hosp Med J; 1989; 37(3-4):175-7. PubMed ID: 2576958
[TBL] [Abstract][Full Text] [Related]
9. [The assessment of clinical usefulness of 131I-MIBG scintigraphy for localization of tumors of sympathetic and adrenomedullary origin--a report of multicenter phase III clinical trials].
Sasaki Y; Kubo A; Kusakabe K; Masaki H; Endo K; Yamashita M; Nakajo M; Kaneko M
Kaku Igaku; 1992 Sep; 29(9):1083-98. PubMed ID: 1360549
[TBL] [Abstract][Full Text] [Related]
10. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors.
Limouris GS; Giannakopoulos V; Stavraka A; Toubanakis N; Vlahos L
Anticancer Res; 1997; 17(3B):1589-92. PubMed ID: 9179199
[TBL] [Abstract][Full Text] [Related]
11. Radionuclide imaging in medullary thyroid carcinoma: evaluation of two new radiopharmaceuticals.
Clarke SE; Lazarus CR; Maisey MN
Henry Ford Hosp Med J; 1987; 35(2-3):124-6. PubMed ID: 2826368
[No Abstract] [Full Text] [Related]
12. [Scintigraphy of medullary carcinoma of the thyroid by new radiopharmaceuticals].
Tada J; Konishi J; Torizuka K; Makimoto K; Miyauchi A
Rinsho Hoshasen; 1984 Sep; 29(9):1043-4. PubMed ID: 6096600
[No Abstract] [Full Text] [Related]
13. Thyroid uptake of MIBG in Sipple's syndrome.
Perdrisot R; Rohmer V; Lejeune JJ; Bigorgne JC; Jallet P
Eur J Nucl Med; 1988; 14(1):37-8. PubMed ID: 2898364
[TBL] [Abstract][Full Text] [Related]
14. Iodine 131 metaiodobenzylguanidine scintigraphy of medullary carcinoma of the thyroid.
Skowsky WR; Wilf LH
South Med J; 1991 May; 84(5):636-41. PubMed ID: 1852077
[TBL] [Abstract][Full Text] [Related]
15. Imaging of medullary thyroid carcinoma and hyperfunctioning adrenal medulla using iodine-131 metaiodobenzylguanidine.
Ansari AN; Siegel ME; DeQuattro V; Gazarian LH
J Nucl Med; 1986 Dec; 27(12):1858-60. PubMed ID: 2878066
[TBL] [Abstract][Full Text] [Related]
16. Multiple endocrine neoplasia type 2 with malignant pheochromocytoma--long term follow-up of a case by 131I-meta-iodobenzylguanidine scintigraphy.
Namba H; Kondo H; Yamashita S; Kimura H; Yokoyama N; Tsuruta M; Sato A; Izumi M; Kinoshita H; Hakariya S
Ann Nucl Med; 1992 May; 6(2):111-5. PubMed ID: 1352456
[TBL] [Abstract][Full Text] [Related]
17. Metastatic medullary thyroid cancer: localization with iodine-131 metaiodobenzylguanidine.
Sone T; Fukunaga M; Otsuka N; Morita R; Muranaka A; Yanagimoto S; Tomomitsu T; Nakayama H; Harada T
J Nucl Med; 1985 Jun; 26(6):604-8. PubMed ID: 3158726
[TBL] [Abstract][Full Text] [Related]
18. New tracers for the imaging of the medullary thyroid carcinoma.
Guerra UP; Pizzocaro C; Terzi A; Giubbini R; Maira G; Pagliaini R; Bestagno M
Nucl Med Commun; 1989 Apr; 10(4):285-95. PubMed ID: 2544835
[TBL] [Abstract][Full Text] [Related]
19. More on [99mTc](V)DMSA scintigraphy in patients with medullary carcinoma of the thyroid.
Mojiminiyi OA; Udelsman R; Shepstone BJ; Dudley NE; Soper ND
J Nucl Med; 1989 Aug; 30(8):1420. PubMed ID: 2547036
[No Abstract] [Full Text] [Related]
20. Detection of hepatic metastasis from medullary thyroid cancer with Tc-99m-MIBI scintigraphy in a patient with Sipple's syndrome.
Sato S; Okumura Y; Tamizu A; Maki K; Akaki S; Takeda Y; Kanazawa S; Hiraki Y
Ann Nucl Med; 2001 Oct; 15(5):443-6. PubMed ID: 11758951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
